Blood test could detect deadly pancreatic cancer in early stages

Updated 2017-07-13 13:51:41 Xinhua

U.S. researchers said Wednesday they have developed a new blood test that may help doctors correctly identify patients with early-stage pancreatic cancer, a disease often diagnosed too late for cure.

In a study published in the U.S. journal Science Translational Medicine, researchers at the University of Pennsylvania said the test, based on a pair of blood biomarkers, detected early stage of the disease in lab experiments with 98 percent sensitivity and 87 percent specificity, meaning that it accurately identified 98 percent of patients with and 87 percent of those without the disease.

"A long standing concern has been that patients with pancreatic cancer are often not diagnosed until it is too late for the best chance at effective treatment," Robert Vonderheide, director of the university's Abramson Cancer Center (ACC), who was not involved in the study, said in a statement.

"Having a biomarker test for this disease could dramatically alter the outlook for these patients," Vonderheide said.

Currently over 53,000 people in the United States are diagnosed with pancreatic cancer -- the fourth leading cause of cancer death -- every year.

Most of the patients with pancreatic cancer are diagnosed during advanced stages of the disease, and their tumors are not surgically resectable, leading to an overall five-year survival rate of merely seven percent.

To develop urgently-needed early-detection methods, the researchers evaluated 746 cancer and control human blood samples using an inexpensive, commercially available protein-detection assay.

The team found that blood levels of plasma thrombospondin-2 (THBS2), combined with levels of a known later-stage biomarker called CA19-9, was reliable at detecting the presence of pancreatic cancer in patients.

Their results were validated in a follow-up study that analyzed samples from 197 pancreatic cance patients, 140 healthy controls, and 200 people with non-cancer pancreatic disorders.

"Positive results for THBS2 or CA19-9 concentrations in the blood consistently and correctly identified all stages of the cancer," said Ken Zaret, director of the Penn Institute for Regenerative Medicine, who led the study.

"Notably, THBS2 concentrations combined with CA19-9 identified early stages better than any other known method."

The team anticipated that the combination THBS2 and CA19-9 could serve as a low cost, noninvasive screening tool in individuals with a high risk of developing pancreatic cancer, including those who have a first-degree relative with pancreatic cancer, who are genetically predisposed to the disease, or who had a sudden onset of diabetes after the age of 50.

Also in the News

Nicole Kidman Recalls Oscar Glory: Loneliest Time
Showbiz2016/06/16 13:58July 17 2018 04:21:49

Nicole Kidman Recalls Oscar Glory: Loneliest Time

Attending Shanghai International Film Festival, Nicole Kidman talks about her role in "Grace of Monaco".

Labor Day Travel Peak Starts
Also in the News2014/05/01 12:16July 17 2018 04:21:49

Labor Day Travel Peak Starts

Johnny Depp Delivers a Speech 'Evolve the Future' in 'Transcendence'
Also in the News2014/04/18 13:18July 17 2018 04:21:49

Johnny Depp Delivers a Speech 'Evolve the Future' in 'Transcendence'

Hollywood star Johnny Depp's speech in the upcoming new film "Transcendence" has been disclosed on Friday, April 11th.

Most Watched

China World Business Sports Showbiz Audio
C4 My Chinese Life The Sound Stage China Revealed Showbiz Video Travel Video
China World Fun Travel Entertainment Sports
Beijing Shanghai Guangzhou
Live Music Opera & Classical Movies Traditional Shows Exhibitions
Learn Chinese:
Chinese Studio Living Chinese Everyday Chinese Just For Fun Chinese Culture Buzzwords